abstract |
The present invention addresses the problem of providing polytherapy with improved antitumor effect over administration of a Trk inhibitor or various kinase inhibitors alone. According to the present invention, a Trk inhibitor, in particular a compound represented by the general formula (I) (in the formula, all symbols are as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, is useful as an active ingredient of a cancer therapeutic agent used in combination with one or more drugs selected from the group consisting of an inhibitor MEK, a CDK4 / 6 inhibitor, an EGFR inhibitor, and a JAK1 / 2 inhibitor. |